What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “NVG-291 is an investigational peptide therapeutic administered by subcutaneous injection. Participants randomized to the experimental arm will receive NVG-291 once daily for 12 weeks. NVG-291 is designed to promote nervous system repair and functional recovery following chronic spinal cord injury.”In the company’s words, NCT07799532 on ClinicalTrials.gov
- Tested for
- Chronic Spinal Cord Injury
- Main trialPhase 3
- “The goal of this clinical trial is to learn if NVG-291 can improve function in adults with chronic cervical motor-incomplete spinal cord injury. It will also learn about the safety of NVG-291. The main questions it aims to answer are: * Does NVG-291 improve hand function and daily activities? * What side effects do participants have when taking NVG-291? Researchers will compare NVG-291 to a placebo (a look-alike substance that does not contain NVG-291) to see if NVG-291 improves function in adults with chronic cervical motor-incomplete spinal cord injury. Participants will: * Take NVG-291…”In the company’s words, NCT07799532 on ClinicalTrials.gov
Other drugs for Chronic Spinal Cord Injury
- AST-OPC1Lineage Cell Therapeutics, Inc. · Phase 1
Coming up1
- Jul 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Jul 2027 | A Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury | |
| Phase 1/2Completed | 31 Dec 2025 | NVG-291 in Spinal Cord Injury Subjects | |
| Phase 1Completed | 4 Jun 2023 | A Phase I Safety Study of NVG-291 in Healthy Adults |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026